JP2020530293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530293A5 JP2020530293A5 JP2020506964A JP2020506964A JP2020530293A5 JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5 JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5
- Authority
- JP
- Japan
- Prior art keywords
- place
- seq
- sequence
- ala
- polypeptide comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 387
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 387
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 387
- 239000000539 dimer Substances 0.000 claims description 45
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 7
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 6
- 230000008499 blood brain barrier function Effects 0.000 claims description 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 230000000447 dimerizing effect Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543658P | 2017-08-10 | 2017-08-10 | |
| US62/543,658 | 2017-08-10 | ||
| US201762583314P | 2017-11-08 | 2017-11-08 | |
| US62/583,314 | 2017-11-08 | ||
| USPCT/US2018/018371 | 2018-02-15 | ||
| PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
| PCT/US2018/046199 WO2019032955A1 (en) | 2017-08-10 | 2018-08-10 | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530293A JP2020530293A (ja) | 2020-10-22 |
| JP2020530293A5 true JP2020530293A5 (enExample) | 2021-09-16 |
| JP7280241B2 JP7280241B2 (ja) | 2023-05-23 |
Family
ID=65272509
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506964A Active JP7280241B2 (ja) | 2017-08-10 | 2018-08-10 | 操作されたトランスフェリン受容体結合ポリペプチド |
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20200289627A1 (enExample) |
| EP (2) | EP3665192B1 (enExample) |
| JP (4) | JP7280241B2 (enExample) |
| CN (2) | CN111148757B (enExample) |
| CA (2) | CA3072051A1 (enExample) |
| DK (1) | DK3665192T5 (enExample) |
| ES (1) | ES2956062T3 (enExample) |
| FI (1) | FI3665192T3 (enExample) |
| HR (1) | HRP20231118T1 (enExample) |
| HU (1) | HUE063021T2 (enExample) |
| LT (1) | LT3665192T (enExample) |
| MD (1) | MD3665192T2 (enExample) |
| PL (1) | PL3665192T3 (enExample) |
| PT (1) | PT3665192T (enExample) |
| RS (1) | RS64584B1 (enExample) |
| SI (1) | SI3665192T1 (enExample) |
| SM (1) | SMT202300347T1 (enExample) |
| TW (1) | TWI821197B (enExample) |
| WO (2) | WO2019032955A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| EP3840781A1 (en) * | 2018-08-22 | 2021-06-30 | Denali Therapeutics Inc. | Anti-her2 polypeptides and methods of use thereof |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) * | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US20250066449A1 (en) * | 2021-12-31 | 2025-02-27 | Imnewrun, Inc. | Blood-brain barrier permeable fusion protein and uses thereof |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| IL318627A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| CN120112164A (zh) | 2022-07-29 | 2025-06-06 | 瑞泽恩制药公司 | 包含修饰的转铁蛋白受体基因座的非人动物 |
| MA71631A (fr) | 2022-07-29 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblées vers le récepteur 1 de transferrine |
| EP4634218A2 (en) * | 2022-12-16 | 2025-10-22 | Denali Therapeutics Inc. | Methods and compositions related to engineered transferrin receptor-binding molecules |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2026052652A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382812A1 (en) * | 1999-08-30 | 2001-03-08 | Joseph Schlessinger | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| CN103443125B (zh) * | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| SG11201509566RA (en) * | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| PL3092251T3 (pl) * | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
| EP3145945B1 (en) * | 2014-05-22 | 2020-07-15 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| CA2967830A1 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| EP3221361B1 (en) * | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CA3053381A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en not_active Ceased
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 CN CN201880063660.0A patent/CN111148757B/zh active Active
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en not_active Ceased
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 SM SM20230347T patent/SMT202300347T1/it unknown
- 2018-08-10 DK DK18756531.2T patent/DK3665192T5/da active
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
-
2020
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en not_active Abandoned
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en not_active Abandoned
-
2025
- 2025-05-30 JP JP2025090730A patent/JP2025120209A/ja active Pending
-
2026
- 2026-03-03 US US19/555,622 patent/US20260191935A1/en active Pending